Prevalence and predictors of cervical lesions among women on ART in the Awi Zone, Northwest Ethiopia: facility-based cross-sectional study Authors: Kelemework Gashinet Ferede, Berihun Bantie, Asiya Mohammed Abdu, Addisu Gasheneit Ferede, Daniel Shitu Mekonnen, Gebiaw Wudie Thegaye Published: 2025 ABSTRACT BackgroundPrecancerous and suspicious cervical cancer lesions refer to abnormal changes in cervical cells that may develop into malignancy if left untreated. Women living with Human Immunodeficiency Virus (HIV) face a significantly higher burden of AIDS-defining malignancies, particularly invasive cervical cancer. Their risk of developing cervical cancer is approximately six times greater than that of HIV-negative women. Despite the elevated risk, there is limited evidence in understanding the prevalence of cervical lesions among women living with HIV (WLHIV) who undergo cervical cancer screening in Ethiopia. This gap underscores the need for further research to inform targeted interventions and improve health outcomes for these high-risk populations.MethodsA facility-based cross-sectional study was conducted among 583 adult WLHIV in the Awi Zone, Northwest Ethiopia. Both primary and secondary data were collected between January and May 2023 to address the study objectives. Data were entered into Epidata version 4.6 and exported to SPSS version 26 for analysis. A bivariable and multivariable binary logistic regression model was fitted to identify factors associated with the outcome variable. Statistical significance was determined at a p-value of less than 0.05 and a 95% confidence interval (CI).ResultsThe magnitude of precancerous and/or suspicious cervical cancer lesions (PCCLs) among women living with HIV was 24.9% (95% CI: 21.3–28.1%). The likelihood of developing precancerous and suspicious cervical cancer lesions was higher among individuals with a baseline CD4 + cell count of < 200 cells/mm³ (AOR = 3.82, 95% CI: 2.44–5.39), a history of sexually transmitted infections other than HIV (AOR = 3.97; 95% CI: 1.97–5.70), use of oral contraceptives (AOR = 2.18; 95% CI: 1.40–3.40), having two or more sexual partners (AOR = 2.86; 95% CI: 1.79–4.55), fair adherence to antiretroviral therapy (ART) (AOR = 2.81; 95% CI: 1.39–5.64), and poor ART adherence (AOR = 3.25; 95% CI: 1.87–7.43).ConclusionIn this study, a relatively high prevalence of precancerous lesions was found among WLHIV compared to previous studies in Ethiopia. Behavioral, clinical, and reproductive health-related factors were linked to the occurrence of the disease. These findings underscore the importance of giving special attention to high-risk women through targeted screening and preventive interventions.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12905-025-04163-7. Introduction Cervical lesions are abnormal tissue growth on the cervix, the lower part of the uterus. These lesions can be precancerous and suspicious cervical lesions which have the potential to develop into cervical cancer (CC) if not treated early [1]. Precancerous cervical lesions are abnormal changes in cervical cells that are not yet cancerous but progress to cancer if untreated, while suspicious cervical cancer lesions refer to visible abnormalities or cytological findings that raise suspicion of a potential malignancy but necessitate additional diagnostic confirmation, such as a biopsy or colonoscopy [2, 3]. Persistent infection with human papillomavirus (HR-HPV) is the primary causes of these lesions, and their detection presents a vital chance for prompt treatment and halting the spread of cancer [4]. Women living with HIV (WLHIV) are particularly vulnerable due to weakened immune systems, which reduce their ability to clear HR-HPV, leading to faster progression of cervical lesions and cancer [5]. Cervical Cancer (CC), on the other hand, is the fourth most common cancer among women living with HIV [6, 7]. Women living with HIV are disproportionately affected by invasive cervical cancer and face a devastating burden from this malignancy [8, 9]. Notably, the risk of acquiring CC is six times greater in WLHIV than in women without HIV [7, 10]. This risk highly varies globally, with WLHIV in Latin America and Africa experiencing disproportionately higher rates [11]. Cervical cancer in turn is the leading causes of cancer related mortality in WLHIV, with much of the burden falling in low- and middle-income countries (LMICs) [12], where 90% of death occurs [6]. The co-infection of CC and HIV/AIDS has also other severe consequences, including reduced quality of life, impaired body image and sexual function, significant financial difficulties, social stigma, and increased rates of depression [13–15]. It also decreases life expectancy and survival rates, with half of comorbid women dying in less than two years and places an additional burden on the healthcare system [12, 16, 17]. Moreover, when coexisting with HIV, this malignancy exhibits more aggressive clinical behavior, such as rapid progression from high-risk HPV infection to cervical cancer, earlier age of onset, more advanced stage at presentation, higher rates of recurrence following treatment, and poor treatment outcomes [18–20]. Several factors, such as socio-demographic and behavioral characteristics, prior cervical cancer screening (CCS) history, and the clinical conditions of WLHIV, contribute to the increased burden of CC-HIV co-infection [21–31]. However, CC is a preventable and treatable disease that can be effectively controlled by expanding HPV vaccination, enhancing regular screening and early detection efforts, and ensuring timely treatment of precancerous lesions [32, 33]. In this context, the WHO launched the 90-70-90 CC elimination initiative as a global strategy. This strategy aims for 90% of girls to be fully vaccinated with the HPV vaccine by age 15, 70% of women to be screened twice in their lifetimes at ages 35 and 45 years, and 90% of women with detected precancerous lesions to receive appropriate treatment to eliminate CC as a public health issue by 2030 [34]. Specifically, WLHIV aged 25–49 years are strongly advised to undergo HPV DNA testing every 3 to 5 years [35]. Correspondingly, Ethiopia’s CC prevention policy also recommended that WLHIV aged 15–49 be screened for CC using visual inspection with acetic acid (VIA) [36]. While the HPV DNA testing is the preferred screening method, VIA remains the most feasible and practical option in many resource-limited settings, including Ethiopia. Despite existing recommendations, the majority of WLHIV in Ethiopia have limited or no access to CCS, and the incidence of cervical cancer continues to rise [37, 38]. Globally, the number of CC cases is projected to reach about 700,000 by 2030, with almost 400,000 related deaths. This represents a 21% increase in incidence and a 27% increase in mortality [10]. Although studies have been conducted in Ethiopia, many have not considered the cervical cancer screening status of HIV, which may lead to an underestimation of the true prevalence of the disease. Including unscreened women in the study population dilutes the accuracy of prevalence estimates, as their disease status remains unknown. To obtain a reliable estimate of cervical cancer prevalence among WLHIV, it is essential to include only those who have undergone cervical cancer screening. Thus, this study aimed to explore the prevalence and factors associated with precancerous and suspicious cervical cancer lesions among WLHIV in the Awi Zone, Northwest Ethiopia. Methods and materials Study design, setting and period A facility-based cross-sectional study was conducted at public health institutions in the Awi Zone, Northwest Ethiopia. The Awi Zone, located in the northwestern part of Ethiopia, is administratively divided into nine woredas and three town administrations [39]. As of 2023, the total population of the zone was 1,342,324, of whom 684,590 (51%) were female. Women of reproductive age (15–49 years) comprised approximately 22.5% of the total female population [40]. An estimated 6,230 people in the Awi Zone are living with HIV/AIDS, of whom 3,759 are women of reproductive age. Among these women, 3,428 have been screened for cervical cancer. The zone delivers healthcare services through fifty-four health facilities, including forty-nine health centers and five hospitals. However, only 24 of these facilities currently provide antiretroviral therapy (ART) services, and just 20 offer cervical cancer screening for women living with HIV [41, 42]. Population All adult women aged 18 years and older living with HIV who were screened for cervical cancer (CC) and were available during the study period at the selected health facilities were included in the study. Women were excluded if they were unable to provide information or lacked records for key variables such as age and CD4 + cell count. Sample size and sampling The sample size was determined using a single population proportion formula, based on the assumptions of a 95% confidence level, a 5% margin of error, and a 22.1% prevalence of precancerous cervical lesions among women’s living with HIV as reported in a previous study conducted in Southern Ethiopia [43]. After accounting for a 10% non-response rate and applying a design effect of two, the final calculated sample size was 583. A multistage sampling technique was used to select the eligible study participants. Initially, eight health facilities namely Ingabire General Hospital (IGH), Danglla Health center (DHC), Gimjabet Health center (GHC), Tilili Health center (THC), Chagni Health center (CHC), Addis-kidam Health center (AHC), Injibara Health center (IHC) and Chagni Primary Hospital (CPH) were randomly selected (using lottery method approach) from a total of 20 health facilities that provide both ART and CC screening services in the Awi zone. The total number of women living with HIV (WLHIV) who received CC screening services and had follow-up visits during the data collection period was subsequently obtained from each selected health facility (n = 1044) to serve as a sampling frame. The total sample was then proportionally allocated to the selected health facilities to reduce potential selection bias. Finally, the eligible study participants were selected using a systematic sampling method. In this process, when patients arrived at the ART clinics for follow-up, their charts were arranged in order. From the first randomly selected facility, the initial sample was chosen using a lottery method from numbers 1 to k. Subsequently, all 583 individuals were selected using a k-interval of 2 (k = 2) (Fig. 1).Fig. 1A schematic presentation of the sampling techniques for the prevalence and predictors of cervical lesions among WLHIV in Awi Zone, Northwest Ethiopia, 2023 A schematic presentation of the sampling techniques for the prevalence and predictors of cervical lesions among WLHIV in Awi Zone, Northwest Ethiopia, 2023 Study variables The outcome variable for this study was the presence of precancerous or suspicious cervical cancer lesions among WLHIV, categorized as either “yes” or “no.” Precancerous cervical lesions involve early cellular changes that may progress to cancer if untreated, while suspicious lesion are abnormalities that appears to be severe enough to suggest they may already be cancerous as identified through Visual Inspection with Acetic Acid (VIA) [3]. The independent variables consisted of sociodemographic factors (age, marital status, place of residence, and educational level), clinical factors (CD4 + count, viral load, duration of ART therapy, WHO clinical stage of HIV, previous cervical cancer screening status, and adherence to ART follow-up), and the behavioral and reproductive characteristics of women living with HIV (age at first sexual intercourse, number of sexual partners, smoking history, parity history, history of long-term oral contraceptive (OC) use, and history of abortion). ART drug adherence was defined as the percentage of antiretroviral therapy (ART) medication taken from the prescribed monthly dose and was categorized as good, fair, or poor [29]. Women who took more than 95% of their ART medication correctly or missed only ≤ 2 doses per month were considered to have good adherence. Those who took 85–95% of their ART medication or missed 3–5 doses per months. CD4 cell count refers to the number of CD4 + T lymphocytes per microliter (µL) of blood, expressed as cells/µL [44]. The duration of ART therapy was measured in terms of years. Data collection tools and procedures Both primary and secondary data collection methods were deployed from January to May 2023. Data on participants’ sociodemographic, reproductive, behavioral, and clinical characteristics were collected using pretested, semi-structured questionnaires adapted from previous literature, as well as through a review of medical records [21–23, 26, 29–31]. The questionnaire was initially prepared in English, translated into Amharic by language experts experienced in research writing and publication, and then back translated into English to ensure consistency and accuracy (Supplementary file 1). To proceed with the data collection, eligible study participants were asked for their consent to participate in the study, and the data were collected through face-to-face interviews. Moreover, clinical and treatment-related variables were retrieved from patient charts. The data were collected by five trained BSc nurses and four health officers (HOs) who received comprehensive ART care training and worked in the ART clinic. Furthermore, the data collection activity was closely supervised by assigned supervisors at each health facility. Data quality control Data quality was ensured through several measures. First, data collectors and supervisors received two days of training by the principal investigator covering the study objectives, procedures for extracting relevant data, appropriate approaches for engaging with study participants, and methods for maintaining confidentiality. A pretest was conducted with thirty women living with HIV at Finoteselam Primary Hospital to assess the clarity, understandability, and simplicity of the questionnaire. Based on the feedback from the pretest, the questionnaire was reviewed and revised before the actual data collection period. Each day, the collected data were reviewed by the supervisors for completeness and consistency and then submitted to the principal investigator to ensure adherence to the study protocol. Statistical analysis The data were entered into EpiData version 4.6 and exported to SPSS version 26 for further statistical analysis. Pairwise deletion was used to manage missing data when the proportion of missing values was less than 20%. Descriptive statistics, including frequency, mean, and median, were used to summarize the characteristics of the study participants. Bivariable and multivariable binary logistic regression analyses were conducted to identify candidate and significant variables, respectively. Variables with a p-value ≤ 0.2 in the bivariable analysis were included in the multivariable logistic regression model. The associations between the outcome and explanatory variables were assessed using multivariable logistic regression. Variables with a p-value < 0.05 were considered statistically significant factors associated with CC-HIV co-infection. Moreover, the model fitness was checked using the Hosmer–Lemeshow goodness-of-fit test, and the results were deemed fit at a p-value of 0.47. We performed a pseudo-linear regression analysis to assess the presence of multicollinearity among independent variables using the Variance Inflation Factor (VIF), and the VIF score was found to be 2.3. Finally, the results were presented in tables, graphs, and charts. Ethical considerations The ethical approval letter was obtained from the Institutional Review Board (IRB) of Bahir Dar University, College of Medicine, and Health Sciences, with protocol number 593/2022. All methods in the manuscript were conducted in accordance with relevant ethical guidelines and regulations established by the Declaration of Helsinki. After receiving ethical clearance, permission was issued by the Awi Zone Health Department, and an official letter of cooperation was obtained from the selected health facilities. After explaining the purpose and significance of the study, verbal informed consent was obtained from each participant prior to their inclusion in the study. Anonymity was maintained to ensure confidentiality by eliminating the names and other personal identifiers of participants throughout the study process and in the final report. Reporting of the manuscript hits the STROBE checklist for cross-sectional studies (SF.2). Results Socio-demographic characteristics of the study participants A total of 578 (99%) WLHIV who were screened for cervical cancer (CC) were enrolled in the study. The ages of the study participants ranged from 24 to 52 years, with nearly half 272 (47.1%) of the participants aged between 30 and 45 years. Regarding their place of residence, the majorities,433 (74.9%) were urban dwellers. Additionally, a large majority, 469 (81.1%) of the study participants had a formal education (Table 1). Table 1Sociodemographic characteristics of WLHIV in the Awi zone, Northwestern Ethiopia, 2023 (n = 578)VariablesCategoriesFrequency (%)Age (in years)< 30129 (22.3)30–45272 (47.1)≥ 46177 (30.6)ResidencyUrban433 (74.9)Rural145 (25.1)ReligionOrthodox469 (81.1)Muslim64 (11.1)Protestant45 (7.8)Educational statusNo formal education109 (18.9)Primary school106 (18.3)Secondary school208(36.0)Tertiary school155(26.8)Marital statusMarried309 (53.5)Unmarried81 (14.0)Widowed73(12.6)Divorced/separated115(19.9)OccupationDaily labourer38 (6.6)Government employee61 (10.6)MerchantFarmer214(37.0)132 (22.8)Housewife133 (23.0) Table 1Sociodemographic characteristics of WLHIV in the Awi zone, Northwestern Ethiopia, 2023 (n = 578)VariablesCategoriesFrequency (%)Age (in years)< 30129 (22.3)30–45272 (47.1)≥ 46177 (30.6)ResidencyUrban433 (74.9)Rural145 (25.1)ReligionOrthodox469 (81.1)Muslim64 (11.1)Protestant45 (7.8)Educational statusNo formal education109 (18.9)Primary school106 (18.3)Secondary school208(36.0)Tertiary school155(26.8)Marital statusMarried309 (53.5)Unmarried81 (14.0)Widowed73(12.6)Divorced/separated115(19.9)OccupationDaily labourer38 (6.6)Government employee61 (10.6)MerchantFarmer214(37.0)132 (22.8)Housewife133 (23.0) Sociodemographic characteristics of WLHIV in the Awi zone, Northwestern Ethiopia, 2023 (n = 578) Merchant Farmer 214(37.0) 132 (22.8) Behavioral and reproductive characteristics of the study participants Among the 578 participants, nearly half, 286 (49.5%) started their first sexual intercourse between the ages of 15 and 20, and 267 (46.2%) reported having more than or equal to two sexual partners. In contrast, only 22 (3.8%) of the participants reported that they always use condoms during sexual intercourse. Regarding reproductive history, 254 (43.9%) had a parity history of five or more, and 198 (34.3%) reported a history of abortion. Similarly, only 40 (8.9%) of the participants had their first delivery before the age of eighteen. The majority, 505 (87.4%) of the study participants had never had a previous history of CCS (Table 2). Table 2Behavioral and reproductive characteristics of WLHIV on antiretroviral therapy in the Awi zone, Amhara region, Northwest Ethiopia, 2023 (n = 578)VariablesCategoriesFrequency (%)Age at start of first sexual intercourse< 15107 (18.5)15–20286 (49.5)≥ 20185 (32.0)Numbers of sexual partnersOnly one311(53.8)Two and above267(46.2)Parity history of womenNull Para127(22.0)Para I-IV197(34.1)≥ 5 Para V254 (43.9)Age at first delivery< 18 years40 (8.9)≥ 18 years411 (91.1)History of menstrual irregularityYes161(27.9)No417 (72.1)Family history of cervical cancerYesNo27(4.7)551(95.3)History of abortionYesNo198(34.3)380(65.7)Numbers of abortionOnly oneTwo and above58(29.3)140(70.7)History of hormonal oral contraceptive useYes233(40.3)No345(59.7)Condom use during sexual intercourseNever435(75.3)Sometimes121(20.9)Always22 (3.8)Ever history of cigarette smokingYes30 (5.2)No547 (94.8)Previous pre cervical cancer screening historyYes73 (12.6)No505(87.4)Frequency of previous cervical cancer screeningOnly one56 (76.7)Two and above17 (23.3) Table 2Behavioral and reproductive characteristics of WLHIV on antiretroviral therapy in the Awi zone, Amhara region, Northwest Ethiopia, 2023 (n = 578)VariablesCategoriesFrequency (%)Age at start of first sexual intercourse< 15107 (18.5)15–20286 (49.5)≥ 20185 (32.0)Numbers of sexual partnersOnly one311(53.8)Two and above267(46.2)Parity history of womenNull Para127(22.0)Para I-IV197(34.1)≥ 5 Para V254 (43.9)Age at first delivery< 18 years40 (8.9)≥ 18 years411 (91.1)History of menstrual irregularityYes161(27.9)No417 (72.1)Family history of cervical cancerYesNo27(4.7)551(95.3)History of abortionYesNo198(34.3)380(65.7)Numbers of abortionOnly oneTwo and above58(29.3)140(70.7)History of hormonal oral contraceptive useYes233(40.3)No345(59.7)Condom use during sexual intercourseNever435(75.3)Sometimes121(20.9)Always22 (3.8)Ever history of cigarette smokingYes30 (5.2)No547 (94.8)Previous pre cervical cancer screening historyYes73 (12.6)No505(87.4)Frequency of previous cervical cancer screeningOnly one56 (76.7)Two and above17 (23.3) Behavioral and reproductive characteristics of WLHIV on antiretroviral therapy in the Awi zone, Amhara region, Northwest Ethiopia, 2023 (n = 578) Yes No 27(4.7) 551(95.3) Yes No 198(34.3) 380(65.7) Only one Two and above 58(29.3) 140(70.7) Clinical status of women living with HIV on ART follow-up In this study, among 578 women on ART follow-up, 266 (46.0%) had more than 5 years of follow-up. Similarly, approximately 244 (42.2%) and 267 (46.2%) participants had a CD4 count < 200 cell/mm3 and were in an advanced WHO clinical stage at the baseline of ART follow-up. Only 129 (22%) women had good adherence to ART drugs. Furthermore, 385 (66.6%) and 310 (53.6%) patients had other opportunistic infections and had a history of STIs other than HIV during their lifetime (Table 3). Table 3Clinical/medical conditions of women receiving ART in the Awi Zone, Amara region, Northwest Ethiopia, 2022/23 (n = 578)VariablesCategoriesFrequency (%)Duration on ART follow-up (in years)1–5 years103 (17.8)5–10 years209 (36.2)Greater than ten years266 (46.0)Baseline CD4 countLess than 200244 (42.2)200 and above334 (57.8)Recent CD4 countLess than 200121 (20.9)Greater than or equals to 200457 (79.1)Baseline WHO clinical stageNot in advanced stage311 (53.8)Advanced stage267 (46.2)Recent WHO clinical stagesWHO stage I/II258 (44.6)WHO stage III/IV320 (55.4)History of STIs other than HIVYes310 (53.6)No268 (46.4)Other opportunistic infections (OIs)Yes385 (66.6)No193 (33.4)History of long -term steroid drug useYes171 (29.6)No407 (70.4)Adherence status of women living with HIV on ART drugsGood129 (22.3)Fair224 (38.8)Poor225 (38.9) Table 3Clinical/medical conditions of women receiving ART in the Awi Zone, Amara region, Northwest Ethiopia, 2022/23 (n = 578)VariablesCategoriesFrequency (%)Duration on ART follow-up (in years)1–5 years103 (17.8)5–10 years209 (36.2)Greater than ten years266 (46.0)Baseline CD4 countLess than 200244 (42.2)200 and above334 (57.8)Recent CD4 countLess than 200121 (20.9)Greater than or equals to 200457 (79.1)Baseline WHO clinical stageNot in advanced stage311 (53.8)Advanced stage267 (46.2)Recent WHO clinical stagesWHO stage I/II258 (44.6)WHO stage III/IV320 (55.4)History of STIs other than HIVYes310 (53.6)No268 (46.4)Other opportunistic infections (OIs)Yes385 (66.6)No193 (33.4)History of long -term steroid drug useYes171 (29.6)No407 (70.4)Adherence status of women living with HIV on ART drugsGood129 (22.3)Fair224 (38.8)Poor225 (38.9) Clinical/medical conditions of women receiving ART in the Awi Zone, Amara region, Northwest Ethiopia, 2022/23 (n = 578) Prevalence of precancerous and suspicious cervical cancer lesions In the current study, 144 (24.9%; 95% CI: 21.3%–28.1%) of WLHIV were found to have cervical lesions. Among them, 115 (19.9%) had precancerous cervical lesions, while 29 (5.0%) were suspected to have invasive cervical cancer lesions (Fig. 2).Fig. 2The prevalence of precancerous and suspicious cervical cancer lesions among WLHIV on in the Awi zone, northwest Ethiopia, 2023 The prevalence of precancerous and suspicious cervical cancer lesions among WLHIV on in the Awi zone, northwest Ethiopia, 2023 Factors associated with precancerous and suspicious cervical cancer lesions According to the bivariable binary logistic regression model, a total of 10 variables with a value < 0.20 were considered candidate variables for multivariable binary logistic regression. In the final model, the following five variables, namely, the adherence status of WLHIV on ART drugs, baseline CD4 count, ever history of STIs, hormonal oral contraceptive use, and number of sexual partners, were identified as statistically significant predictors of co-infection of CC in WLHIV. In this context, mothers who used contraceptives were twice as likely to develop cervical cancer co-infection than those who had not used contraceptives (AOR = 2.18, 95% CI: 1.40–3.40). Women with a baseline CD4 count less than 200 cells/mm³ were approximately four times more likely to develop cervical cancer comorbidity than individuals with a baseline CD4 count > 200 cells/mm³ (AOR = 3.82, 95% CI: 2.44–5.39). Additionally, women with a history of STIs other than HIV were almost four times more likely to acquire precancerous and suspicious cervical cancer lesions than were those without such a history of STIs (AOR = 3.97, 95% CI = 1.97–5.70). Moreover, women having two or more sexual partner are nearly three times more likely to have precancerous and suspicious cervical cancer lesions among individuals with more than one lifetime sexual partner than among their counterparts (AOR = 2.86, 95% CI = 1.79–4.55). Similarly, women with fair or poor adherence to ART drugs were almost three times more likely to have precancerous and suspicious cervical cancer lesions than were those with good adherence (AOR = 2.80, 95% CI = 1.39–5.64; AOR = 3.25, 95% CI = 1.87–7.43 (Table 4).Table 4Bivariable and multivariable logistic regression analyses of factors associated with precancerous and suspicious cervical cancer lesions comorbidity among WLHIV in the Awi Zone, Northwest Ethiopia, 2023 (n = 578)VariablesCategoriesPrecancerous and suspicious cervical cancer-lesions statusCOR (95% CI)AOR (95% CI)P valuesPositiveNegativeAge at first sexual intercourse<1535722.16 (1.25–3.74)1.67(0.66–3.21)0.12715–20752111.58 (1.01–2.49)1.31(0.77–2.23)0.325> 2034151111Hormonal contraceptive useYes841492.68 (1.82–3.94)2.18 (1.40–3.40)0.001*No6028511Baseline CD4< 200911533.15 (2.13–4.67)3.82 (2.44–5.99)0.001*≥ 20053281111History of abortionYes641341.79 (1.22–2.64)1.34 (0.83–2.14)0.229No803001Numbers of sexual partners≥Two1041634.32 (2.86–6.53)2.86 (1.79–4.56)0.001*One40271111Duration on ART drug> 10 years191752.496(1.34–4.66)1.64(0.79–3.38)0.1785–10 years154552.27 (1.19–4.32)2.10 (0.99–3.19)0.059< 5 years8914111History of STIs other than HIVYes1171935.41(3.42–8.57)3.97(2.39–6.59)0.001*No27241111Baseline WHO stageStage III/IV821851.78 (1.22–2.61)1.10 (0.69–1.75)0.69Stage I/II62249111Adherence to ART drugsGood141151Fair571672.80(1.49–5.27)2.81 (1.39–5.64)0.004*Poor731523.95 (2.12–7.34)3.25(1.87–7.43)0.001*Numbers of parityNull para19108111Para I-IV501471.93(1.08–3.47)0.59 (0.31–1.12)0.104>Para V751792.38(1.36–4.156)0.86(0.52–1.42)0.56CD4- Clusters of differentiation, STIs- sexual transmitted infections, *- statistically significant predictors of co-infection of Precancerous and suspicious cervical cancer-lesions status among women’s living with HIV/AIDS; COR Crude Odds Ratio, AOR Adjusted Odds Ratio Table 4Bivariable and multivariable logistic regression analyses of factors associated with precancerous and suspicious cervical cancer lesions comorbidity among WLHIV in the Awi Zone, Northwest Ethiopia, 2023 (n = 578)VariablesCategoriesPrecancerous and suspicious cervical cancer-lesions statusCOR (95% CI)AOR (95% CI)P valuesPositiveNegativeAge at first sexual intercourse<1535722.16 (1.25–3.74)1.67(0.66–3.21)0.12715–20752111.58 (1.01–2.49)1.31(0.77–2.23)0.325> 2034151111Hormonal contraceptive useYes841492.68 (1.82–3.94)2.18 (1.40–3.40)0.001*No6028511Baseline CD4< 200911533.15 (2.13–4.67)3.82 (2.44–5.99)0.001*≥ 20053281111History of abortionYes641341.79 (1.22–2.64)1.34 (0.83–2.14)0.229No803001Numbers of sexual partners≥Two1041634.32 (2.86–6.53)2.86 (1.79–4.56)0.001*One40271111Duration on ART drug> 10 years191752.496(1.34–4.66)1.64(0.79–3.38)0.1785–10 years154552.27 (1.19–4.32)2.10 (0.99–3.19)0.059< 5 years8914111History of STIs other than HIVYes1171935.41(3.42–8.57)3.97(2.39–6.59)0.001*No27241111Baseline WHO stageStage III/IV821851.78 (1.22–2.61)1.10 (0.69–1.75)0.69Stage I/II62249111Adherence to ART drugsGood141151Fair571672.80(1.49–5.27)2.81 (1.39–5.64)0.004*Poor731523.95 (2.12–7.34)3.25(1.87–7.43)0.001*Numbers of parityNull para19108111Para I-IV501471.93(1.08–3.47)0.59 (0.31–1.12)0.104>Para V751792.38(1.36–4.156)0.86(0.52–1.42)0.56CD4- Clusters of differentiation, STIs- sexual transmitted infections, *- statistically significant predictors of co-infection of Precancerous and suspicious cervical cancer-lesions status among women’s living with HIV/AIDS; COR Crude Odds Ratio, AOR Adjusted Odds Ratio Bivariable and multivariable logistic regression analyses of factors associated with precancerous and suspicious cervical cancer lesions comorbidity among WLHIV in the Awi Zone, Northwest Ethiopia, 2023 (n = 578) CD4- Clusters of differentiation, STIs- sexual transmitted infections, *- statistically significant predictors of co-infection of Precancerous and suspicious cervical cancer-lesions status among women’s living with HIV/AIDS; COR Crude Odds Ratio, AOR Adjusted Odds Ratio Discussion This study aimed to assess the prevalence of precancerous and suspicious cervical cancer-lesions and its associated factors among WLHIV in the Awi zone, northwest Ethiopia. The study revealed that the overall prevalence of cervical cancer lesions comorbidity among WLHIV in the Awi Zone was 24.9% (95% CI: 21.3%–28.1%). This figure is in line with previous studies in Kenya (26.4%), SSA (25.6%), Tanzania (26.7%), Switzerland (22.9%), and India (24.06%) [5–47]. However, the result of this study is slightly greater than those of previous studies in Ethiopia, including those conducted at referral hospitals in the Amhara region (20.2%) [48], Eastern Ethiopia (17.8%) [49], and Northwest Ethiopia (9.3%) [50]. This discrepancy may be due to differences in inclusion criteria; the current study included only women who had undergone cervical cancer screening. In contrast, earlier studies assessed the prevalence of CC among WLHIV without accounting for the implementation status of CC screening in health facilities. Additionally, the increased scale of CC screening in recent years compared to previous periods may also explain the higher incidence observed. The more WLHIV are screened for CC, the greater the probability of obtaining a positive case. Furthermore, this figure is also higher than those reported in previous studies conducted in Zambia (15%) [51], Nigeria (19%, 19.5% and 12.8%)[52, 53], Namibia (17%) [54], and Spain (18%) [55]. The sources of heterogeneity in these findings could be differences in CC screening techniques which had a various sensitivity and specificity rate [51, 56, 57]. This finding indicates that co-infections of cervical cancer in WLHIV is significant public health concern in the study area. They underscore the need to scale up CC screening programs by integrating screening services into the exiting antiretroviral therapy (ART) program. Service integration has been proposed as a feasible, acceptable, and cost-effective approach to improve uptake, early detection, and timely management of lesions, particularly in areas with high HIV prevalence and limited resources [58, 59]. On the other hand, the above finding was also lower than those of previous studies in South Africa [60]; Zambia 52% [57]; and Cameron (68.18%) [61].The higher prevalence reported by the other studies could be due to the behavioral and sexual characteristics of the women studied, such as age at first sexual debut and the number of sexual partners. As women have frequent exposure to sexual intercourse with different people, the risk of acquiring HPV increases, leading to CC [62, 63]. Furthermore, this could be partly explained by variation in methods of screening for CC [57]; the more variation in the measurements, the more varied the result will be due to the varied specificity and sensitivity of each screening method [51, 56, 57]. In the present study, a history of sexually transmitted diseases (STDs) was significantly associated with the occurrence of precancerous or suspicious cervical cancer (CC) lesions in the Awi Zone, Northwest Ethiopia. Women living with HIV who had previously contracted an STD were nearly four times more likely (AOR = 3.97) to experience co-infections compared to those without such a history. This result is consistent with previous studies conducted in referral hospitals in the Amhara region of Northwest Ethiopia [25, 26], in the Saint Peter specialized hospital in Addis Ababa, Ethiopia [64], and in different African countries, such as Nigeria and Uganda [22, 46, 65]. An explanation could be that HPV infection is more prevalent in STI patients due to its sexually transmitted nature. Co-infection with STI and HPV amplifies the risk of CC by causing inflammation, which enables HPV persistence and adherence. This severely affects immune-compromised women, increasing their vulnerability to other opportunistic infections, including CC [66]. The above figure suggests that screening for HPV and precancerous cervical lesions (PCCLs) needs to be performed for all women with STIs. A significant association was also detected between lifetime numbers of sexual partners and presence of precancerous and suspicious cervical cancer-lesions. A woman who had more than one lifetime sexual partner were almost three (2.86) times more likely to have PCCL than women who had only one lifetime sexual partner. This pattern has also been seen in previous studies performed in Northeast Ethiopia [26]; referral hospitals in the Amhara region; and northwest Ethiopia [25] and in Mekelle, northwest Ethiopia [67]. Similar results have also been reported in studies from sub-Saharan African countries [5] and Swaziland [46]. The increased risk may be attributed to the greater likelihood of acquiring human papillomavirus (HPV) infection as the number of sexual partners increases. This finding underscores the importance of integrating sexual behavior assessments into routine HIV care, promoting safer sexual practices, and strengthening sexual health education to reduce cervical cancer comorbidity in this population. The odds of developing precancerous and suspicious cervical cancer-lesions among women who took OC were almost two times greater (2.19) than those among women who did not take OC. These findings are supported by previous studies in Debre Markos Comprehensive Specialized Referral Hospital and Adama References Hospital in western Kenya and by a systematic review and meta-analysis [49, 68–70]. A possible elucidation for this difference might be that prolonged use of oral contraceptives may increase the eversion of the columnar epithelium of the cervix to the ectocervix, which enhances the exposure of the columnar epithelium to HPV infection, the main cause of almost all CCs [69]. This finding suggests that further investigation into the biological mechanisms hormonal influence on cervical epithelium and HPV susceptibility need to warrant. WLHIV, those who use OCs therefore might benefit from more frequent cervical cancer screening. The odds of developing having precancerous and suspicious cervical cancer lesions was almost fourfold greater (3.82) among women who had a baseline CD4 + cell count ≤ 200 cells/mm³ than among their counterparts. This result is in agreement with studies conducted in Woldia and Mekelle Comprehensive Specialized Hospital, Northwest Ethiopia [67, 71]. It is also supported by a study in Tanzania [63] and systematic review and meta-analysis studies in Africa and globally [70, 72, 73]. The reason may be that lower CD4 + levels weaken the immune system, making it harder for women to fight off HPV infections [72]. HIV-induced immune suppression reduces the body’s ability to clear HPV, increasing the risk of cervical cancer [47, 72]. The above finding highlighted that reducing vulnerability to cervical cancer comorbidity is highly dependent on maintaining women’s immune status. Hence, it may be beneficial to initiate a cotrimoxazole preventive therapy (CPT) booster dose for patients with low CD4 + T cells. Furthermore, adherence to ART drugs was also significantly associated with the presence of precancerous and suspicious cervical cancer-lesions among WLHIV. In this study, the odds of having precancerous and suspicious cervical cancer lesions were 2.81 and 3.25 times higher, respectively, WLHIV who had poor and fair ART adherence compared to those with good adherence. An explanation could be that ART with good adherence boosts women’s immunity and reduces their tendency to develop PCCLs. This could also be explained by the fact that HAART lowers HPV acquisition and increases clearance via immune reconstitution, decreasing the risk of progression from a precancerous lesion to cervical cancer [73, 74]. The finding recommends that improving adherence to antiretroviral therapy (ART) among WLHIV is crucial for reducing the burden of cervical cancer comorbidity. Key strategies include peer education and community support, enhancing ART accessibility at the primary health care level, and addressing broader social and economic barriers. Limitations of the study This study has several limitations that need to be considered while interpreting the result. First, due to the cross-sectional nature of the study, causal relationships are difficult to establish, and potential confounding variables like behavioral and health system-related factors were not fully captured in this study. Secondly, variables such as age at first sexual intercourse and number of sexual partners were collected retrospectively, which may introduce recall bias and social desirability bias, potentially affecting the accuracy of the data. Thirdly, the use of visual inspection with acetic acid (VIA) for cervical cancer screening may have limited sensitivity. As a result, some visually apparent precancerous cervical lesions (PCCLs) could have been missed, potentially leading to an underestimation of the true prevalence of cervical cancer comorbidity. Finally, the absence of confirmatory diagnostic methods for individuals with suspicious cervical lesions, such as biopsy or cytology, could have resulted in an overestimation of cervical lesions among WLHIV. Conclusion and recommendations In this study, the prevalence of precancerous or suspicious cervical cancer lesions among women living with HIV was relatively high compared to previous studies conducted in Ethiopia. Several factors were found to be significantly associated with these lesions, including poor adherence to antiretroviral therapy (ART), low baseline CD4 + T-cell count, a history of sexually transmitted infections (STIs) other than HIV, use of hormonal oral contraceptives, and having more than two sexual partners. Therefore, stakeholders should provide due attention and increase awareness regarding the risks associated with having multiple sexual partners and their link to cervical cancer Furthermore, strong counseling on ART adherence and giving due emphasis to individuals with low CD4 + T-cell count are essential to improve immune function and reduce the risk of comorbidity. Supplementary Information Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2